JP2016011317A - ゲノム編集用クリスパーキャス9による老化遺伝子切り取り若返り経口不老不死薬7 - Google Patents
ゲノム編集用クリスパーキャス9による老化遺伝子切り取り若返り経口不老不死薬7 Download PDFInfo
- Publication number
- JP2016011317A JP2016011317A JP2015206961A JP2015206961A JP2016011317A JP 2016011317 A JP2016011317 A JP 2016011317A JP 2015206961 A JP2015206961 A JP 2015206961A JP 2015206961 A JP2015206961 A JP 2015206961A JP 2016011317 A JP2016011317 A JP 2016011317A
- Authority
- JP
- Japan
- Prior art keywords
- oral
- immortal
- rejuvenation
- medicine
- elderly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 12
- 230000003716 rejuvenation Effects 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 title claims description 12
- 230000032683 aging Effects 0.000 title claims description 10
- 238000010362 genome editing Methods 0.000 title abstract description 7
- 101100328957 Caenorhabditis elegans clk-1 gene Proteins 0.000 claims abstract description 3
- 108020005004 Guide RNA Proteins 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 5
- 230000008672 reprogramming Effects 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 102000055501 telomere Human genes 0.000 claims description 3
- 108091035539 telomere Proteins 0.000 claims description 3
- 210000003411 telomere Anatomy 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 claims description 2
- -1 L-Myc Proteins 0.000 claims description 2
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 2
- 101150086694 SLC22A3 gene Proteins 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 210000004958 brain cell Anatomy 0.000 claims description 2
- 210000004720 cerebrum Anatomy 0.000 claims description 2
- 210000004211 gastric acid Anatomy 0.000 claims description 2
- 210000001320 hippocampus Anatomy 0.000 claims description 2
- 101150111214 lin-28 gene Proteins 0.000 claims description 2
- 239000002775 capsule Substances 0.000 abstract description 2
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 2
- 101150090724 3 gene Proteins 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
【解決手段】ヒトiPS6因子である初期化するのに必要なものを用意し経口し初期化しておき、clk-1、elt-5、elt-6等の老化遺伝子を見つけ切り取るガイドRNAを含む、クリスパーキャス9をカプセルに入れるかコーティングするかして経口式にすることで口から飲むという単純化とし、このようにして老化遺伝子すべてが切り取られ望むならば若さを保つ遺伝子導入で若返りも可能なゲノム編集を施した、以上のような特徴を持つゲノム編集用クリスパーキャス9による老化遺伝子切り取り若返り経口不老不死薬7
【選択図】なし
Description
以上のような特徴を持つゲノム編集用クリスパーキャス9による老化遺伝子切り取り若返り経口不老不死薬7。
Claims (1)
- (a)主として高齢老人のヒトiPS6因子である初期化するのに必要なOct3/4、Sox2、Klf4、L−Myc、Lin28、Nanogを用意し経口し初期化しておき、
(b)clk-1、elt-5、elt-6等の老化遺伝子を見つけ切り取るガイドRNAを含む、(c)クリスパーキャス9をカプセルに入れて胃酸や熱で壊れないようにするか、コーティングするかして、たんぱく質のクリスパーキャス9「酵素たんぱく質ハサミ」で、
(d)従来、これを血液中に入れていたが、これを経口式にすることで口から飲むという単純化とし、
(e)このようにして高齢老人でも全細胞が初期化しテロメアも若返ったように元の長さに戻り、経口不老不死薬となるが脳細胞の初期化で記憶も甦るか、脳の中の海馬と大脳を光刺激か電極刺激して全記憶が甦り老人脳も若くなるし、老化遺伝子すべてが切り取られ望むならば若さを保つ遺伝子導入で若返りも可能なゲノム編集を施した、
以上のような特徴を持つゲノム編集用クリスパーキャス9による老化遺伝子切り取り若返り経口不老不死薬7
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015206961A JP2016011317A (ja) | 2015-10-21 | 2015-10-21 | ゲノム編集用クリスパーキャス9による老化遺伝子切り取り若返り経口不老不死薬7 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015206961A JP2016011317A (ja) | 2015-10-21 | 2015-10-21 | ゲノム編集用クリスパーキャス9による老化遺伝子切り取り若返り経口不老不死薬7 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2016011317A true JP2016011317A (ja) | 2016-01-21 |
Family
ID=55228244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015206961A Pending JP2016011317A (ja) | 2015-10-21 | 2015-10-21 | ゲノム編集用クリスパーキャス9による老化遺伝子切り取り若返り経口不老不死薬7 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2016011317A (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016188256A (ja) * | 2016-08-08 | 2016-11-04 | 加治佐 功 | 脳slendr法・体テロメラーゼクリスパーキャス9老化細胞除去ゲノム編集無病不老不死製法3 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008283972A (ja) * | 2005-12-13 | 2008-11-27 | Kyoto Univ | 誘導多能性幹細胞の製造方法 |
-
2015
- 2015-10-21 JP JP2015206961A patent/JP2016011317A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008283972A (ja) * | 2005-12-13 | 2008-11-27 | Kyoto Univ | 誘導多能性幹細胞の製造方法 |
JP2009165480A (ja) * | 2005-12-13 | 2009-07-30 | Kyoto Univ | 誘導多能性幹細胞およびその製造方法 |
Non-Patent Citations (2)
Title |
---|
JPN6015047371; 生物物理 54(5), 2014, p.247-252 * |
JPN6015047372; 脳21 18(3), 20150720, p.203-210,112 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016188256A (ja) * | 2016-08-08 | 2016-11-04 | 加治佐 功 | 脳slendr法・体テロメラーゼクリスパーキャス9老化細胞除去ゲノム編集無病不老不死製法3 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nowak et al. | Aspects of the epigenetic regulation of EMT related to cancer metastasis | |
Zuccarini et al. | The role of Wnt signal in glioblastoma development and progression: a possible new pharmacological target for the therapy of this tumor | |
EA202191313A1 (ru) | Композиции на основе липидных наночастиц | |
BR112018068391A2 (pt) | sistema e métodos para produzir uma proteína, célula inoculada, construção de rna para expressar a replicase de alfavírus e dna | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
EA201991255A1 (ru) | Регулируемая транскрипция | |
EA201890456A1 (ru) | Новый слитый полипептид, специфичный в отношении lag-3 и pd-1 | |
BR112019022512A2 (pt) | Compostos de heteroarila bicíclica fundida 6-6 e seu uso como inibidores de lats | |
EP3468356A4 (en) | GENETICALLY MODIFIED CELLS, TISSUES AND ORGANS FOR THE TREATMENT OF A DISEASE | |
SG10201906673WA (en) | Artificial nucleic acid molecules | |
EP4406585A3 (en) | Nucleic acid products and methods of administration thereof | |
CY1123343T1 (el) | Παραγωγη μιας τραπεζας μεσεγχυματικων στρωματικων κυτταρων απο τα ομαδοποιημενα μονοπυρηνα κυτταρα πολλαπλων δοτων μυελου των οστων | |
JP2021102659A (ja) | エピゲノム編集とgls1阻害剤両用若返り経口不老不死薬8 | |
RU2015149010A (ru) | Биологические маркеры, которые могут быть использованы в иммунотерапии рака | |
WO2015118537A3 (en) | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions | |
Yang et al. | Melatonin suppresses hypoxia-induced migration of HUVECs via inhibition of ERK/Rac1 activation | |
AU2018269275A1 (en) | Five- and six-membered aza-aromatic compound, preparation method therefor, pharmaceutical composition, and application | |
WO2017053732A3 (en) | Composition and method for treating complement-mediated disease | |
Strippoli et al. | Contribution of autophagy to epithelial mesenchymal transition induction during cancer progression | |
Kot et al. | Boosting neurogenesis in the adult hippocampus using antidepressants and mesenchymal stem cells | |
JP2016011317A (ja) | ゲノム編集用クリスパーキャス9による老化遺伝子切り取り若返り経口不老不死薬7 | |
Hu et al. | HMGCS2-induced autophagic degradation of tau involves ketone body and ANKRD24 | |
EP3529234A4 (en) | COMPOUNDS, METHOD FOR OBTAINING THE COMPOUNDS, PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR THE TREATMENT OF PSYCHIATRIC AND / OR SLEEP DISORDERS | |
BR112018077225A2 (pt) | proteínas de fusão tatk-cdkl5, composições, formulações e uso das mesmas | |
JP2008163042A (ja) | ヒトiPS細胞初期化3遺伝子利用経口不老不死薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20151021 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20151118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151201 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160104 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20160104 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160202 |